Key Points
- Director Stan Smith purchased 13,740 shares on December 5 at $1.20 per share, and has acquired roughly 57,970 shares in recent trades (about $66,000 total) across Oct–Dec.
- MAIA stock jumped 9.8%, opening at $1.35; the company has a market cap of about $50 million, a 52‑week range of $0.87–$2.74, and negative earnings with analysts forecasting roughly -1.3 EPS for the year.
- Institutional activity includes Centric Wealth Management raising its stake to 573,398 shares, and overall institutional ownership of the stock is about 5.65%.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith acquired 13,740 shares of the company's stock in a transaction that occurred on Friday, December 5th. The shares were acquired at an average cost of $1.20 per share, for a total transaction of $16,488.00. Following the completion of the transaction, the director directly owned 4,580 shares of the company's stock, valued at $5,496. The trade was a -150.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Stan Smith also recently made the following trade(s):
- On Tuesday, November 25th, Stan Smith bought 15,000 shares of MAIA Biotechnology stock. The stock was bought at an average cost of $0.98 per share, with a total value of $14,700.00.
- On Monday, November 24th, Stan Smith acquired 10,000 shares of MAIA Biotechnology stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $9,900.00.
- On Wednesday, October 1st, Stan Smith acquired 19,230 shares of MAIA Biotechnology stock. The stock was bought at an average price of $1.30 per share, with a total value of $24,999.00.
MAIA Biotechnology Stock Up 9.8%
NYSEAMERICAN MAIA opened at $1.35 on Wednesday. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $2.74. The company has a market capitalization of $49.99 million and a P/E ratio of -1.85. The stock's 50-day moving average price is $1.28 and its 200-day moving average price is $1.53.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.08). Research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.
Institutional Trading of MAIA Biotechnology
Institutional investors and hedge funds have recently modified their holdings of the company. Centric Wealth Management lifted its stake in shares of MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company's stock valued at $1,032,000 after buying an additional 505,150 shares in the last quarter. Geode Capital Management LLC raised its holdings in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock valued at $400,000 after acquiring an additional 7,746 shares during the period. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology in the second quarter valued at about $52,000. Marshall Wace LLP bought a new position in shares of MAIA Biotechnology in the second quarter worth about $29,000. Finally, Centerpoint Advisory Group purchased a new stake in shares of MAIA Biotechnology during the second quarter worth about $28,000. 5.65% of the stock is currently owned by institutional investors.
About MAIA Biotechnology
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
